|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024485,
umls-concept:C0030695,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0871261,
umls-concept:C1516119,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1999216,
umls-concept:C2239176,
umls-concept:C2911692
|
|
pubmed:dateCreated |
2009-7-23
|
|
pubmed:abstractText |
New therapeutic principles in clinical oncology require the adjustment of response criteria to govern therapy decisions. For advanced hepatocellular carcinoma (HCC) a new era has recently begun by the approval of the multikinase inhibitor sorafenib. As a unique feature, HCC usually develops in a diseased liver and current imaging technologies employing classical response criteria have not been prospectively evaluated for this new treatment.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-10074914,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-15466206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-16829648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-16890795,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-16908937,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17016424,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17160391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17178294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17178882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17215530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17470685,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17631592,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-17968956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-18650514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-19068275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-19091547,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-19097774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19558720-7563311
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
208
|
|
pubmed:dateRevised |
2010-9-27
|
|
pubmed:meshHeading |
pubmed-meshheading:19558720-Adult,
pubmed-meshheading:19558720-Aged,
pubmed-meshheading:19558720-Antineoplastic Agents,
pubmed-meshheading:19558720-Benzenesulfonates,
pubmed-meshheading:19558720-Carcinoma, Hepatocellular,
pubmed-meshheading:19558720-Female,
pubmed-meshheading:19558720-Humans,
pubmed-meshheading:19558720-Liver,
pubmed-meshheading:19558720-Liver Neoplasms,
pubmed-meshheading:19558720-Magnetic Resonance Imaging,
pubmed-meshheading:19558720-Male,
pubmed-meshheading:19558720-Middle Aged,
pubmed-meshheading:19558720-Necrosis,
pubmed-meshheading:19558720-Protein Kinase Inhibitors,
pubmed-meshheading:19558720-Pyridines,
pubmed-meshheading:19558720-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
|
|
pubmed:affiliation |
Department of Gastroenterology & Hepatology, Medical University Hospital, Eberhard-Karls-University, D-72076 Tübingen, Germany. marius.horger@med.uni-tuebingen.de
|
|
pubmed:publicationType |
Journal Article
|
